In the U.S. alone, there are over 100 million chronic wound visits every year. By 2020, the general wound care market is expected to hit about $20.5 billion. Maryland’s Gemstone Biotherapeutics aims to address this market with a highly tunable, novel biosynthetic wound healing product that is heading towards FDA review. Now with a 2019 Maryland Stem Cell Research Fund (MSCRF) grant award they are drawing a lot of attention as a company to watch in the regenerative medicine space.
{iframe}http://www.biobuzz.inloop.com/en/article/67126?utm_source=ElasticEmail-sb-biobizHub&utm_medium=newsletter&utm_campaign=biobizHub-460-s-en-011118{/iframe}